Browsing Tag
Hart-Scott-Rodino Act
4 posts
SunOpta’s Refresco sale is closer now, but the real closing risk has not fully disappeared
SunOpta has cleared a major antitrust hurdle in its Refresco buyout. Read what the approval changes, what risks remain, and what it means for STKL.
NVRI near 52-week high as Enviri clears final regulatory hurdle for $3.04bn Clean Earth sale to Veolia
Enviri (NVRI) clears HSR antitrust review for $3B Clean Earth sale to Veolia. SEC filings due this month. What happens next for NVRI investors? Read more.
Merger war explodes: Pfizer drags Metsera and Novo Nordisk to court over ‘illegal’ bid
Pfizer takes legal action against Metsera and Novo Nordisk over breach of merger terms. Find out how this battle could reshape obesity drug M&A.
Merck licenses innovative anti-cancer therapy LM-299 from LaNova Medicines
In a strategic move to broaden its oncology portfolio, Merck & Co., Inc. (NYSE: MRK), recognized globally as…